Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TGRX-678 |
Synonyms | |
Therapy Description |
TGRX-678 inhibits BCR-ABL1 and ABL1 mutations including T315I, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Blood (2023) 142 (Supplement 1): 2807). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TGRX-678 | TGRX 678|TGRX678 | ABL1 Inhibitor 8 BCR-ABL Inhibitor 32 | TGRX-678 inhibits BCR-ABL1 and ABL1 mutations including T315I, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Blood (2023) 142 (Supplement 1): 2807). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06088888 | Phase I | TGRX-678 | TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia | Recruiting | USA | 0 |